Study to Evaluate Safety/Duration in Stomach of Extended Release Capsules Containing Memantine Hydrochloride in Healthy Adults

Early Phase 1CompletedNCT03711825

Lyndra Inc.8 enrolled

Overview

To assess how long memantine hydrochloride (HCl) (50 mg) extended release capsules stay in the stomach as determined by imaging assessment (MRI or abdominal ultrasound). To evaluate the safety of a memantine HCl extended release capsule formulation

This is a single centre, open label, single dose study in healthy adult subjects. Eligible individuals will be admitted to an inpatient unit in two or more cohorts. Enough eligible individuals will be admitted allowing for the enrollment of the Sentinel (n= 2) and Main Group (total of n=8 in Main), and an optional Supplemental Group (n= 6), if required. All enrolled subjects will be dosed with a single administration of an extended release capsule containing memantine hydrochloride (LYN-057), 50 mg. Dosing will be conducted in an inpatient clinical unit, with access to an acute care facility. Subjects will remain in the inpatient unit for 7 days after dosing. During this time, subjects will undergo intermittent imaging assessments for gastric retention \[magnetic resonance imaging (MRI) and abdominal ultrasound (U/S)\], safety assessments, blood sampling for evaluation of memantine pharmacokinetics (PK), and faecal collections for assessments of formulation components and bowel movement characteristics. Subjects will return to the clinic for PK sampling and safety assessments on Days 10, 15, 22 and Day 29 (End of Study Visit). In addition, some subjects may continue to perform faecal collection and/or may undergo imaging assessments on Day 10 based on clinical criteria. On Day 29 (End of Study Visit), subjects will undergo final safety and PK assessments and will be discharged from the study.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Alzheimer Disease Gastric Retention Healthy

Interventions

LYN-057DRUG

Administration of single dose of LYN-057 presented as extended release capsule containing 50 mg of memantine hydrochloride (HCl)

Imaging Assessment (MRI)PROCEDURE

Imaging assessments \[MRI\] will be performed on specified days according to protocol

Imaging Assessment (U/S)PROCEDURE

Imaging assessments (abdominal U/S) will be performed on specified days according to protocol

Eligibility

Sex: ALLMin age: 18 YearsMax age: 40 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Healthy male and female subjects 2. Body mass index of 18.0 to 30.0 kg/meters-squared 3. Suitable scores for two swallowing questionnaires 4. Demonstrate normal swallowing and gastrointestinal passage for capsule, as assessed while undergoing imaging studies 5. Must provide written informed consent Exclusion Criteria: 1. Participants who have previously been enrolled in this study 2. History of any drug or alcohol abuse in the past 2 years 3. Current smokers and those who have smoked within the past 12 months 4. Individuals with clinically significant medical history relating to the gastrointestinal tract and potential complications, thereof 5. Individuals with a positive test for HIV, hepatitis B or hepatitis C 6. Individuals who are contraindicated based on memantine HCl 7. Serious adverse reaction or serious hypersensitivity to components of the study formulation or patency capsule 8. Individuals who have received any experimental agent within 30 days (or 5 half-lives), whichever is longer, prior to the date of dosing 9. Individuals with contraindication to MRI imaging 10. Individuals with functional constipation, irritable bowel, or functional diarrhea, as evaluated by standardized questionnaire 11. Individuals with contraindications to elective X-ray based on known or expected radiation exposure

Locations (1)

CMAX

Adelaide, South Australia, Australia

Outcomes

Primary Outcomes

Gastric retention by imaging assessment by MRI

Visualization of formulation/formulation components in stomach by MRI

Time frame: Up to 9 days post-dosing

Gastric retention by imaging assessment by abdominal U/S

Visualization of formulation/formulation components in stomach by abdominal U/S

Time frame: Up to 9 days post-dosing

Safety and tolerability of a single dose of LYN-057 extended release capsule

Safety collected from a combination of the following: Adverse Event (AE) reporting and examinations specified per protocol

Time frame: Through study completion, up to 3 months

Secondary Outcomes

Memantine HCl pharmacokinetics - Maximum Plasma Concentration (Cmax)

Memantine HCl pharmacokinetics - Cmax by validated assay

Time frame: Pre-dose, on day of dosing at 2, 4, 6, 8 and 12 hours post-dosing, thereafter daily during inpatient stay through Day 8. After Day 8, PK sampling on Day 10, 15, 22 and 29.

Memantine HCl pharmacokinetics - Time after administration of maximum plasma concentration (Tmax)

Memantine HCl pharmacokinetics - Tmax by validated assay

Time frame: Pre-dose, on day of dosing at 2, 4, 6, 8 and 12 hours post-dosing, thereafter daily during inpatient stay through Day 8. After Day 8, PK sampling on Day 10, 15, 22 and 29.

Memantine HCl pharmacokinetics - Area Under the Curve (AUC)

Memantine HCl pharmacokinetics - AUC by validated assay

Time frame: Pre-dose, on day of dosing at 2, 4, 6, 8 and 12 hours post-dosing, thereafter daily during inpatient stay through Day 8. After Day 8, PK sampling on Day 10, 15, 22 and 29.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.